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Opsismodysplasia (OPS) is a rare but severe autosomal recessive skeletal chondrodysplasia caused by inactivating mutations in the Inppl1/Ship2 gene. The molecular mechanism leading from Ship2 gene inactivation to OPS is currently unknown. Here, we used our Ship2 Δ/Δ mouse expressing reduced amount of a catalytically-inactive SHIP2 protein and a previously reported SHIP2 inhibitor to investigate growth plate development and mineralization in vivo, ex vivo and in vitro. First, as observed in OPS patients, catalytic inactivation of SHIP2 in mouse leads to reduced body length, shortening of long bones, craniofacial dysmorphism, reduced height of the hyperthrophic chondrocyte zone and to defects in growth plate mineralization. Second, intrinsic Ship2 Δ/Δ bone defects were sufficient to induce the characteristic OPS alterations in bone growth, histology and mineralization ex vivo. Third, expression of osteocalcin was significantly increased in SHIP2-inactivated chondrocyte cultures whereas production of mineralized nodules was markedly decreased. Targeting osteocalcin mRNA with a specific shRNA increased the production of mineralized nodules. Fourth, levels of p-MEK and p-Erk1/2 were significantly increased in SHIP2-inactivated chondrocytes in response to serum and IGF-1, but not to FGF2, as compared to control chondrocytes. Treatment of chondrocytes and bones in culture with a MEK inhibitor partially rescued the production of mineralized nodules, the size of the hypertrophic chondrocyte zone and bone growth, raising the possibility of a treatment that could partially reduce the phenotype of this severe condition.
Altogether, our results indicate that Ship2 Δ/Δ mice represent a relevant model for human OPS. They also highlight the important role of SHIP2 in chondrocytes during endochondral ossification https://doi.org/10. 1016 /j.jbior.2019 .100651 Received 16 May 2019  Received in revised form 30 August 2019; Accepted 3 September 2019 and its different differentiation steps. Finally, we identified a role of osteocalcin in mineralized nodules production and for the MEK-Erk1/2 signaling pathway in the OPS phenotype.
Introduction
Opsismodysplasia (OPS, OMIM 258480) is a rare but severe autosomal recessive skeletal chondrodysplasia clinically characterized by short stature, short limbs, small hands and feet, macrocephaly and a specific facial dysmorphism (Maroteaux et al., 1984; Beemer and Kozlowski, 1994; Tyler et al., 1999; Cormier-Daire et al., 2003) . The clinical outcome is variable, ranging from embryonic or early postnatal lethality to longer survival, which may sometimes reach more than 20 years (Maroteaux et al., 1984; Beemer and Kozlowski, 1994; Tyler et al., 1999; Cormier-Daire et al., 2003; Below et al., 2013; Huber et al., 2013; Iida et al., 2013) . Typical radiographic features include short long bones with markedly delayed epiphyseal mineralization, metaphyseal cupping, short metacarpals and phalanges, and severe platyspondyly. Histological studies on bones from affected OPS individuals are scarce in the literature, but growth plate alterations have been reported. Indeed, increased chondrocyte density and abnormal chondrocytes clustering in the resting zone have been observed, as well as a nearly lack of columnar organization in the proliferative zone and a reduced height and cell density of the hypertrophic zone. The mineralized matrix trabeculae were reported to be either thick or short but always irregular (Tyler et al., 1999; Cormier-Daire et al., 2003; Huber et al., 2013) . These histological alterations were observed in all OPS cases analyzed, but varied markedly in severity among patients, paralleling the variability of the radiological and clinical manifestations (Cormier-Daire et al., 2003) . In 2013, it was reported that OPS is the consequence of homozygous or compound heterozygous mutations in the Inppl1 gene, encoding for the SHIP2 protein (Below et al., 2013; Huber at al., 2013; Iida et al., 2013) . More than 25 different mutations have been detected in OPS individuals, including nonsense, in-frame, missense, frameshift and splice site mutations. Most of them are predicted to severely alter or inactivate the catalytic function of the SHIP2 protein, but the molecular mechanisms of the disease are currently not understood (Below et al., 2013; Huber et al., 2013; Iida et al., 2013; Fradet and Fitzgerald, 2017) . SHIP2 is a member of the inositol polyphosphate 5-phosphatases family and its catalytic activity is directed against both phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) (Giuriato et al., 2002; Zhang et al., 2007; Elong Edimo et al., 2014 Thomas et al., 2017) . In addition to its central catalytic domain, the 1258 amino acids SHIP2 protein contains several motifs known to be involved in protein-protein interactions, meaning that SHIP2 is also a docking protein for specific intracellular molecules. The SHIP2 protein is largely expressed in hematopoietic and non-hematopoietic cells during embryonic and adult life (Schurmans et al., 1999; Muraille et al., 2001) . Functionally, SHIP2 is important for the control of many cellular processes, including cell migration, proliferation and adhesion, endocytosis, as well as for insulin and growth factors signaling (Suwa et al., 2010; Hakim et al., 2012; Dyson et al., 2012; Elong Edimo et al., 2014; Thomas et al., 2017; Ramos et al., 2019) . Analysis of SHIP2 functions in vivo in genetically-modified mice and zebrafish revealed that PI3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) signaling pathways are altered upon SHIP2 total or catalytic knock-out, leading to growth defects (Sleeman et al., 2005; Jurynec et al., 2010; Dubois et al., 2012) . Despite the fact that inactivating mutations in the Inppl1 gene are responsible for OPS chondrodysplasia, the presence of the Ship2 protein in chondrocytes and its role during endochondral ossification are still largely unknown. In this study, we asked whether our Ship2 catalytic knock-out mouse would be a relevant model for human OPS and to analyze the expression and whether this model would be suitable to analyze the role of SHIP2 in chondrocytes during endochondral ossification.
Materials and methods

Mice
Ship2 +/Δ mice were generated on a mixed 129xC57BL/6 genetic background (Dubois et al., 2012) . Ship2 Δ/Δ mice have both Ship2 exons 18 and 19 deleted but still express a truncated and catalytically-inactive SHIP2 protein. All mice were housed in an animal facility with a 12 h light/12 h dark cycle and had free access to food and water throughout the study period. All mouse studies were authorized by the Animal Care Use and Review Committee of the Université de Liège.
Histological analysis
Tibias of 3 weeks old mice were isolated, formalin-fixed, demineralized during 12 h in dc2 qpath solution (11028304; VWR), paraffin-processed, cut, rehydrated and subjected to Hematoxylin-Eosin and Safranin-O Fast Green staining according to standard procedures. Midsagittal sections of the proximal growth plate of the tibia were selected for measurements.
Reconstruction was performed with NRecon software (Bruker). Morphometric 3D analysis of trabecular bone was performed on a 1.5 mm section starting 0.5 mm from the growth plate using CT Analyzer software (Bruker). Morphometric 2D and 3D analysis of cortical bone was performed on a 0.5 mm section starting 3 mm from the growth plate. 3D images of bones were generated using CT Vol software (Bruker). The number of cortical perforations was counted manually on radiographs.
Monolayer culture of primary chondrocytes
Primary chondrocytes were prepared from 2 to 3 day-old newborn mice as described (Jonason et al., 2015) . Briefly, newborn sternum and ribs were dissected and predigested with 3 mg/ml collagenase D (11088866001; Roche) in 1:1 Dulbecco's modified Eagle medium (DMEM)/F-12 medium (11514436; Gibco) at 37°C for 60 min and further digested in 0.5 mg/ml collagenase D at 37°C overnight. Primary chondrocytes were cultured in chondrogenic differentiation medium containing 1:1 Dulbecco's modified Eagle medium (DMEM)/F-12 medium (Gibco), supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), 0.25 g/ml Fungizone (Gibco), 1% L-glutamine (Gibco), 50 μg/ml L-ascorbic acid, 10 mM β-glycerophosphate for 5 days. All cultures were maintained at 37°C in a humidified 5% CO2 incubator in the presence of 10 μM of AS1949490 Ship2 inhibitor (Tocris) or DMSO. The medium was changed every two days. The last day, cells were starved for 4 h in absence of serum, L-ascorbic and β-glycerophosphate. Cells were stimulated with 10 ng/mL mouse IGF-1 (I8779-Sigma) for 5min or mouse FGF-2 (SRP4038-Sigma) for 30min then subjected for Western blotting and immunodetection. The viability of Ship2 +/+ primary chondrocytes was tested using a MTT assay (CGD1-1 KT, Sigma).
Micromass culture of primary chondrocytes and ATDC5 cells
Primary chondrocytes, prepared from 2 to 3 day-old newborn mice as described above, and ATDC5 cells (Sigma, 1 x 10 5 cells/ cm 2 ) were cultured in chondrogenic differentiation medium containing 1:1 Dulbecco's modified Eagle medium (DMEM)/F-12 medium (Gibco), supplemented with 5% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), 1% Lglutamine (Gibco), 1% ITS+1 (Sigma), 50 μg/ml L-ascorbic acid and 10 mM β-glycerophosphate. After 10 days of differentiation, cells were centrifuged to obtain a density of 2 x 10 7 cells/ml. Cell suspension (10 μl) was then placed in 24-well plates (Corning) at the center of each well for 2-3 h before adding chondrogenic differentiation medium, which allowed cells to form 3-dimensional (3D) micromass (Thirion and Berenbaum, 2004; Seriwatanachai et al., 2012) . All cultures were maintained at 37°C in a humidified 5% CO2 incubator in the presence of 10 μM of AS1949490 SHIP2 inhibitor (Tocris) or DMSO. The medium was changed every two days until 14 days.
Transduction of chondrocyte micromass cultures with shRNA-expressing lentiviral preparations
Lentiviral plasmids expressing EGFP, a puromycine resistance gene and a shRNA were purchased to VectorBuilder. Two shRNAs directed against the mouse osteocalcin (Bglap) mRNA (target sequences: 5′-CCTGCTTGTGACGAGCTATCA-3′ and 5′-TGTCCAAGC AGGAGGGCAATA-3′) and one control shRNA (non-target sequence: 5′-CCTAAGGTTAAGTCGCCCTCG-3′) were used. Lentiviral preparations were generated by the Viral Vectors platform of our institute. Briefly Lenti-X 293T cells (Clontech®, 632180) were cotransfected with a pSPAX2 (Addgene®, Cambridge, MA, USA) and a VSV-G encoding vector. Culture supernatants were collected 48 h, 72 h and 96 h post transfection, filtrated (0.2 μM) and concentrated by ultracentrifugation. The lentiviral preparations were then titrated with a qPCR Lentivirus Titration Kit (ABM®, LV900, Richmond, BC, Canada) in order to estimate the number of transducing unit per mL (TU/mL). ATDC5 cells were transduced with lentiviral vectors (30 TU/cell) and then incubated with 5 μg/mL puromycine. Primary chondrocytes were transduced with lentiviral vectors (50 TU/cell) and then incubated with 1 μg/mL puromycine for 3 days. Transduced ATDC5 cells and primary chondrocytes were transferred into 24well plate in micromass and cultured for 14 days to allow mineralization of the matrix.
Quantification of proteoglycan accumulation and mineralizing nodule production
Cell micromasses were cultured in DMSO or 10 μM AS1949490 SHIP2 inhibitor containing differentiation media before proteoglycan accumulation and mineralizing nodule production were quantified on day 7, 14 and 21. The micromasses were washed twice with PBS and fixed for 20 min in 10% formalin (Sigma). They were then incubated with 0.1% alcian blue 8GX (Sigma) in 0.1 M HCl for 2 h to stain proteoglycans, or with 2% alizarin red S (Sigma) in water pH 4.2 for 30 min to stain mineralizing nodules. After being photographed with an Apple® iPhone 6S coupled with a stereomicroscope, the alcian blue dye was extracted with 6 M guanidine-HCl and the alizarin red S dye was extracted with 10% acetic acid. The optical density was determined at 595 nm (alcian blue) and 405 nm (alizarin red S) by standard spectrophotometric method.
Quantification of osteocalcin and osteopontin levels
Levels of mouse GLA-osteocalcin and osteopontin were measured in supernatants from primary sternal chondrocytes cultures using ELISA kits (MK 127 from Takara Bio Inc, Shiga, Japan and EMSPP1from Thermo Fisher scientific, Massachusetts, USA, respectively).
Immunofluorescence
Mouse primary chondrocytes (250000 cells/well in 24-well plate) or ATDC5 cells (40000 cells/well in 24-well plate) were cultured in differentiation medium for 4 days and fixed in 10% formalin (Sigma). Permeabilization was performed with 0.3% Triton X-100 or with cold methanol (−20°C) during 10 min. Non-specific binding sites were blocked by 10% FBS for 60 min at room temperature. Thereafter, samples were incubated at 4°C overnight with 1:200 polyclonal rabbit anti-mouse phospho-ERK primary antibody (#9101 Cell Signaling) or 1:400 polyclonal mouse SHIP2 antibody (sc-166641 Santa Cruz) and then with 1:400 goat antirabbit or anti-mouse coupled with FITC secondary antibodies (Sigma) and DAPI. Regarding the negative control slides, cells were incubated without primary antibody. Images were captured with Nikon A1R microscope and processed with ImageJ®.
Ex vivo culture of mouse metatarsals
Metatarsal bones were isolated from 2 to 3 day-old newborn mice dissected under sterile conditions. The isolated neonatal bones were cultured in alpha-MEM (Gibco) with 0.2% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), 1% L-glutamine (Gibco), 50 μg/ml L-ascorbic acid, 1 mM β-glycerophosphate. Cultured bones were maintained at 37°C in a humidified 5% CO2 incubator in the presence of vehicle, 10 μM of AS1949490 SHIP2 inhibitor (Tocris) with or without 0.5 μM SL327 MEK inhibitor (Sigma). Bones were measured daily with a stereo-microscope until day 8, fixed in 70% ethanol and stored at 4°C. There were paraffin-processed, cut, rehydrated and subjected to Safranin-O Fast Green and Von Kossa counterstained with Hematoxylin according to standard procedures. 4 midsagittal sections per samples were selected for measurements.
RNA quantification
RNA was isolated from cells by collecting the aqueous phase after phase separation with TRI reagent (Sigma) and chloroform. RNA was precipitated with isopropanol (30 min at −80°C) and centrifuged for 15 min at 20000×g at 4°C. RNA pellets were washed with 75% ethanol. After subsequent ethanol precipitation, RNA was dissolved in DNase/RNase free water. RNA quantity and purity were determined spectrophotometrically (Nanodrop, Thermofisher). Total RNA was reverse transcribed using iScript Synthesis Kits (Biorad). Real time quantitative PCR (RT-qPCR) was performed in 384-well optical plates. For each cDNA sample a mix was prepared consisting of Hot Firepol Evagreen qPCR Mix Plus (Solis Biodyne) and 600 nM forward and reverse oligonucleotides. A Taqman 7900HT Fast Real-time PCR system was used for amplification using the following protocol: denaturation at 95°C for 10 min, followed by 40 cycles of amplification (45 s at 95°C, 1 min at 60°C, 1 min at 75°C) followed by a dissociation curve. Data were analyzed based on the relative quantification of mRNA expression of the target gene normalized to a housekeeping gene (Gapdh). Primer sequences are shown in S1 Table. Gene expression analyses are from representative experiments of at least three independent experiments.
Western blotting and immunodetection
Cells were lysed with protein lysis buffer (50 mM Tris-HCl pH7.4; 100 mM NaCl; 5 mM MgCl 2 ; 5 mM CaCl 2 ; 2% SDS, nuclease (Thermofisher), Phostop (ROCHE) and Protease inhibitor EDTA-free (ROCHE)), briefly sonicated for 20 s and centrifugated at 4°C for 5 min at 10000×g. Proteins were quantified by using the Biorad Protein Assay according to manual instructions. They were denaturated in Laemmi sample buffer at 95°C for 5 min and equivalent amount of proteins were loaded for SDS-PAGE. Protein transfer to nitrocellulose membranes was performed with Biorad Transblot turbo according to kit instructions. Thereafter, membranes were blocked in 5% TBS-Tween 0.5% milk for 1 h prior to overnight incubation with primary antibody at 4°C (1:2000 polyclonal rabbit anti-mouse VINCULIN (#13901 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse phospho-Akt T308 primary antibody (#2965 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse phospho-Akt S473 primary antibody (#4060 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse Akt primary antibody (#4691 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse phospho-MEK primary antibody (#9154 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse MEK primary antibody (#8727 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse phospho-ERK primary antibody (#9101 Cell Signaling); 1:1000 polyclonal rabbit anti-mouse ERK primary antibody (#9102 Cell Signaling); 1:500 polyclonal mouse SHIP2 antibody; 1:1000 polyclonal rabbit anti-mouse OCN primary antibody (AB10911 Merck). After several washes, horseradish peroxidase (HRP)-linked secondary antibody (A9169 Sigma) was added for 1 h at room temperature.
Statistics
Statistical analyses were performed using GraphPad Prism 7 Software (GraphPad Software, San Diego, CA). The statistical test used in each analysis is mentioned in the figure legends. Mice of the same age and the same sex were compared. Data are reported as means ± SD of at least three independent experiments. p < 0.05 was considered significant.
Results
Shortening of bones in Ship2 Δ/Δ mice is associated with a shorter hypertrophic chondrocytes zone, a reduced matrix mineralization and altered metaphysis architecture
After backcrosses for 10 generations with C57BL/6J mice, both male and female C57BL/6J Ship2 Δ/Δ (Ship2 Δ/Δ ) mice still displayed reduced body length and body weight compared with age-and sex-matched C57BL/6J Ship2 +/+ (Ship2 +/+ ) mice, as previously reported for Ship2 Δ/Δ mice on a mixed 129 x C57BL/6J genetic background ( Supplementary Figs. 1A-B , left panels) (Dubois et al., 2012) . These Ship2 Δ/Δ mice also exhibited the characteristic round skull and shortened snout ( Supplementary Fig. 1B , right panel). Skeletal preparations from 3 week-old Ship2 Δ/Δ mice showed proportional shortening of femur and tibia long bones ( Fig. 1A  and B ). Histology of metaphyseal growth plates was examined in tibias of 3 week-old mice. The resting/proliferative chondrocytes zone was similar in Ship2 Δ/Δ and Ship2 +/+ mice. By contrast, the height of the hypertrophic chondrocytes zone was significantly reduced in Ship2 Δ/Δ mice, compared with Ship2 +/+ mice (Fig. 1C and D) . Cell density was normal in resting/proliferative and hypertrophic chondrocytes zones (Fig. 1D ). In order to determine the structural parameters of trabecular bone, micro-computed tomography (micro-CT) analysis of femurs harvested from 20 week-old mice was performed ( Fig. 2A-C) . The most impressive alterations detected in Ship2 Δ/Δ femurs by micro-CT were a reduced length of the primary spongiosa and a decreased trabecular thickness, number and connectivity, compared with Ship2 +/+ mice (Fig. 2C) . By contrast, no difference was observed in femur bone volume and cortical thickness ( Fig. 2A-C) . Altogether, these observations indicate that SHIP2 inactivation in mice resulted in altered endochondral ossification characterized by a shorter hypertrophic chondrocytes zone, a reduced matrix mineralization and altered architecture.
Intrinsic Ship2 Δ/Δ bone factors are sufficient to alter bone growth, histology and mineralization after genetic or pharmacologic SHIP2 inactivation
In order to test if bone intrinsic and/or extrinsic defects resulting from SHIP2 inactivation are essential to induce bone alterations in Ship2 Δ/Δ mice, metatarsals were isolated from 3 day-old Ship2 Δ/Δ and Ship2 +/+ mice and cultured in the same conditions for 8 days. Ex vivo culture of Ship2 Δ/Δ metatarsals reproduced the growth defect observed in vivo in Ship2 Δ/Δ mice (Fig. 3A) . A similar growth defect was observed when Ship2 +/+ metatarsals were cultured in the presence of the AS1949490 Ship2 inhibitor (Fig. 3B) . This AS1949490 inhibitor had no significant effect on the viability of Ship2 +/+ primary chondrocytes which play an essential role in endochondral ossification during bone growth ( Supplementary Fig. 2 ). Histology of metaphyseal growth plates was examined in metatarsals after 8 days of culture. No difference was detected in the resting/proliferative chondrocytes zone when SHIP2 was (caption on next page) C.-A. Vande Catsyne, et al. Advances in Biological Regulation xxx (xxxx) xxxx genetically or pharmacologically inactivated. By contrast, the height of the hypertrophic chondrocytes zone was significantly reduced, as observed above in tibias of Ship2 Δ/Δ mice ( Fig. 3C and E) . The height of the mineralized hypertrophic zone was also significantly reduced in cultured Ship2 Δ/Δ and SHIP2 inhibitor-treated metatarsals, as compared with Ship2 +/+ and DMSO-treated metatarsals, respectively ( Fig. 3D and E) . Thus, our results indicated that intrinsic bone defects secondary to SHIP2 inactivation are sufficient to induce alterations in bone growth, histology and mineralization in Ship2 Δ/Δ mice; our data also confirmed AS1949490 to be a suitable pharmacological tool to reproduce genetic SHIP2 inactivation on bone growth, histology and mineralization.
Genetic and pharmacologic inactivation of SHIP2 leads to reduced matrix mineralization in chondrocyte micromass culture
Chondrocytes play an essential role during endochondral ossification. In order to study the effects of SHIP2 inactivation on chondrocyte differentiation in vitro, a chondrocyte micromass culture was developed from 3 day-old Ship2 Δ/Δ and Ship2 +/+ mouse thoracic cartilage. Using Western blotting followed by immunodetection, the expression of the SHIP2 protein was detected in Ship2 +/ + chondrocyte preparations ( Supplementary Fig. 3A) . After 14 days of culture, chondrocytes isolated from Ship2 +/+ and Ship2 Δ/Δ mice showed similar accumulation of highly sulfated glycosaminoglycans, as measured by alcian blue staining and spectrophotometric quantification (Fig. 4A ). However, when compared with Ship2 +/+ chondrocyte cultures, Ship2 Δ/Δ cultures showed significantly decreased alizarin red S staining, indicative of a markedly reduced production of mineralized nodules (Fig. 4B ). Similar results were obtained when micromass cultures of primary chondrocytes isolated from Ship2 +/+ mice ( Fig. 4C and D) or of the ATDC5 chondrocyte cell line ( Supplementary Figs. 3B-C) were treated with 5-10 μM AS1949490. Indeed, after 7, 14 or 21 days of culture, SHIP2 inhibitor-treated cultures showed a significant decrease in alizarin red S staining/production of mineralized nodules whereas no difference was observed with DMSO-treated culture for alcian blue staining/glycosaminoglycans accumulation.
Altogether, the bone microCT observations in vivo in mice and the in vitro results obtained in chondrocyte micromass cultures indicated that decreased matrix mineralization is an important and reproducible element of the Ship2 Δ/Δ skeletal dysplastic phenotype.
SHIP2 inactivation leads to increased osteocalcin expression in chondrocyte micromass cultures
In order to define the molecular mechanisms of decreased matrix mineralization upon SHIP2 inactivation, the expression of a large set of genes implicated in endochondral ossification was analyzed at the mRNA level in Ship2 Δ/Δ and Ship2 +/+ chondrocyte micromass cultures. Level of specific mRNAs encoding for proteins expressed in resting and proliferative chondrocytes (Acan, Sox-9, PTHrP), prehypertrophic and hypertrophic chondrocytes (IHH) as well as during matrix mineralization (osteocalcin and osteopontin) and osteogenesis (Col1a1) were altered upon genetic SHIP2 inactivation (Fig. 5A) . At the protein level, when compared with Ship2 +/ + chondrocyte micromass culture supernatants, concentrations of carboxylated osteocalcin (GLA-osteocalcin) and osteopontin, both known to be important inhibitors of bone matrix mineralization in vivo (Ducy et al., 1996; Bailey et al., 2017) , were also increased in Ship2 Δ/Δ supernatants (Fig. 5B ). Level of osteocalcin mRNA was also higher in chondrocyte micromass cultures of Ship2 +/+ primary chondrocytes and of ATDC5 cells, a well-established in vitro model of endochondral ossification, upon treatment with 5 μM AS1949490, indicating that both genetic and pharmacologic inactivation of SHIP2 activity led to significant osteocalcin mRNA overexpression (Fig. 5C ).
Targeting osteocalcin mRNA with specific shRNA in SHIP2-inactivated chondrocytes results in an increased matrix mineralization
In order to analyze the role of osteocalcin in the mineralization defect observed when SHIP2 is inactivated, ATDC5 chondrocyte micromass cultures were transduced with lentivirus expressing osteocalcin-specific or scrambled shRNAs and analyzed for mineralized nodules production. In initial experiments, we showed that more than 90% of ATDC5 chondrocytes were GFP positive after transduction with the different GFP-expressing lentiviral preparations ( Supplementary Fig. 4A ) and that two osteocalcin-specific shRNAs led to a significantly decreased level of the osteocalcin protein in chondrocytes ( Supplementary Fig. 4B ) and in the chondrocyte culture supernatant ( Supplementary Fig. 4C ), on the contrary to the scrambled shRNA. When transduced with an osteocalcinspecific shRNA-expressing lentivirus, SHIP2 inhibitor-treated ATDC5 cells produced significantly increased amounts of mineralized nodules, as compared with scrambled shRNA-expressing lentivirus (Fig. 6A) . Similar results were observed in Ship2 Δ/Δ chondrocyte micromass cultures after transduction with osteocalcin-specific shRNA-or scrambled shRNA-expressing lentivirus (Fig. 6B) .
Together, our results indicate that SHIP2 inactivation in chondrocytes increased osteocalcin level and decreased production of mineralized nodules, and that targeting osteocalcin mRNA in these SHIP2-deficient chondrocytes with specific shRNAs increased matrix mineralization. Fig. 6 . Targeting the osteocalcin mRNA with specific shRNA in SHIP2-inactivated chondrocytes results in a significant increase in matrix mineralization. AS1949490 SHIP2 inhibitor-treated (5 μM, AS1949490) ATDC5 cell micromass (A) or Ship2 Δ/Δ chondrocyte micromass (B) cultures were transduced with either a scrambled or an osteocalcin-specific (shOCN) shRNA-expressing lentivirus. After 28 days of culture, mineralized nodule formation (alizarin red S staining) was analyzed. Representative culture plates are presented along with spectrophotometric data. Results shown are representative of 4 independent experiments performed with lentivirus expressing two different osteocalcin-specific shRNAs. Graph shows mean value ± SD. Statistics (paired t-test): *: p < 0.05.
SHIP2 inactivation in chondrocytes leads to increased activation of the MEK-Erk1/2 MAP kinase signaling pathway
In various cell types and models, it has been reported that SHIP2 controls Akt and MAPK signaling pathways in response to insulin, growth factors or serum (Sleeman et al., 2005; Jurynec et al., 2010; Dubois et al., 2012; Agollah et al., 2014; Fafilek et al., 2018; Ramos et al., 2019) . These two signaling pathways were analyzed with phospho antibodies directed against Akt (p-Akt T308 and p-Akt S473 ), MEK (p-MEK) and Erk1/2 (p-Erk1/2). First, using Western blotting followed by immunodetection, it was observed that levels of p-MEK and p-Erk1/2, but not of p-Akt, were significantly increased in Ship2 +/+ chondrocytes cultured with serum in the presence of AS1949490, as compared with DMSO ( Fig. 7A) . Next, increased phosphorylation of Erk1/2 was also shown by immunofluorescence in serum-cultured Ship2 Δ/Δ chondrocytes compared with Ship2 +/+ chondrocytes ( Supplementary Fig. 5A ), as well as in serum-cultured AS1949490-treated ATDC5 cells compared with DMSO-treated cells ( Supplementary Fig. 5B ). Finally, DMSOand SHIP2 inhibitor-treated Ship2 +/+ chondrocytes were stimulated for 5 and 30 min with IGF1 or FGF2, two growth factors that are known to play an important role in chondrocyte differentiation during endochondral ossification (Su et al., 2008; Komori et al., 2011; Wang et al., 2014; Yang et al., 2017) and analyzed for MEK, Erk1/2 and Akt activation. A significantly increased phosphorylation of MEK and Erk1/2, but not of Akt, was observed by Western blotting and immunofluorescence when SHIP2 inhibitor-treated Ship2 +/+ chondrocytes were stimulated with IGF1, as compared to DMSO-treated cells (Fig. 7B and C and Supplementary Fig. 6A ). By contrast, no significant effect was observed on Akt, MEK or Erk1/2 phosphorylations when SHIP2 inhibitor-treated Ship2 +/+ chondrocytes were stimulated with FGF2, as compared with DMSO-treated cells ( Supplementary Fig. 6B ).
Altogether, considering our Western blotting analysis and immunofluorescence data, it appeared that, in mouse chondrocytes, when SHIP2 is inactivated, the MEK-Erk1/2 MAP kinase signaling pathway was significantly and reproducibly upregulated in response to serum and IGF1, but not to FGF2.
Effects of MEK inhibition on in vitro mineralized nodules production and on ex vivo metatarsal bone growth defects resulting from SHIP2 inhibition
Since genetic and pharmacologic inactivation of SHIP2 in chondrocytes resulted in increased serum-and IGF1-stimulated Erk1/2 activation, the effect of MEK inhibition was tested on in vitro mineralized nodules production and on ex vivo metatarsal bone growth. First, the minimal concentration of SL327 MEK inhibitor that restored in SHIP2 inhibitor-treated Ship2 +/+ chondrocytes a level of Erk1/2 phosphorylation similar to DMSO-treated chondrocytes was identified as about 2 μM ( Supplementary Fig. 7 ). Next, when Ship2 Δ/Δ chondrocyte micromass cultures were incubated with 2 μM SL327 MEK inhibitor, the production of mineralized nodules was significantly increased, as compared with DMSO-treated Ship2 Δ/Δ cells (Fig. 8A) . Similar results were obtained in SHIP2 inhibitortreated chondrocytes when incubated with 2 μM SL327 MEK inhibitor (Fig. 8B) . Finally, when SHIP2 inhibitor-treated metatarsal bones were cultured in the presence of 2 μM SL327 MEK inhibitor, a significant increase in metatarsal bone growth ( Fig. 8C ) and in the size of the metatarsal hypertrophic zone (Fig. 8D) were observed, as compared with bones treated with the SHIP2 inhibitor only.
Altogether, these results indicate that targeting with a MEK inhibitor the overactivated MEK-Erk1/2 signaling pathway in SHIP2inactivated chondrocytes resulted in an increased production of mineralized nodules in vitro and an increased metatarsal bone growth and hypertrophic zone size ex vivo.
Discussion
The mechanism leading to OPS, a severe skeletal chondrodysplasia characterized by growth plate defects and delayed bone maturation, is currently unknown. Furthermore, the variability of clinical, radiological and histological manifestations in this rare disease is high (Cormier-Daire et al., 2004; Below et al., 2013; Huber et al., 2013; Iida et al., 2013) , and not all patients have Inppl1 variants, suggesting that OPS exhibits genetic heterogeneity (Below et al., 2013; Iida et al., 2013) . Animal models where SHIP2 is genetically inactivated have been reported in mouse and zebrafish, but they have never been specifically analyzed for bone maturation (Sleeman et al., 2005; Jurynec et al., 2010; Dubois et al., 2012) . We used here our Ship2 Δ/Δ mouse expressing reduced amount of a catalytically-inactive SHIP2 truncated protein to investigate growth plate development and mineralization. As observed in OPS patients, catalytic inactivation of SHIP2 in mouse leads to reduced body length, shortening of long bones, craniofacial dysmorphism, reduced height of the hyperthrophic chondrocytes zone and to defects in growth plate mineralization. However, in our Ship2 Δ/Δ mouse, the diminished body and bone growth is relatively mild in severity and no cellular architectural alteration was detected in the resting and the proliferative zones. This is in contrast to OPS in humans (Tyler et al., 1999; Cormier-Daire et al., 2004; Huber et al., 2013) . These phenotypic differences between human and mouse OPS may reflect interspecies variations, the scarcity and Fig. 7 . Analysis of Akt and MAPK signaling pathways in SHIP2 inhibitor-treated chondrocytes. A. Western blotting with antibodies directed against phospho-and total Akt T308 , Akt S473 , MEK and Erk1/2 proteins on extracts isolated from Ship2 +/+ chondrocytes treated (AS1949490) or not (DMSO) with the AS1949490 SHIP2 inhibitor. Graphs show mean values of phosphoproteins level relative to total Akt, MEK and Erk1/2 protein levels ± SD. Statistics (paired t-test): **: p < 0.01; ***: p < 0.001. B. Ship2 +/+ chondrocytes were treated (AS1949490) or not (DMSO) with the AS1949490 SHIP2 inhibitor and stimulated or not with 13 nM IGF1 for 5 and 30 min. Graphs show mean values of phosphoproteins level relative to total Akt, MEK and Erk1/2 proteins level ± SD. Statistics (paired t-test): *: p < 0.05; **: p < 0.01. A representative Western blotting is presented in S5A Fig. C . Immunofluorescence analysis with an anti-Erk1/2 antibody (green) and DAPI (nuclei, blue) of Ship2 +/+ chondrocytes treated (AS1949490) or not (DMSO) with the AS1949490 SHIP2 inhibitor and stimulated or not with 13 nM IGF1 for 5 min. Scale bars: 40 μm. Results shown are representative of 3 independent experiments. the variability of histological observations reported in OPS patients and/or the precise nature of the Inppl1 mutations in man and mouse. Indeed, in Ship2 Δ/Δ mice, only exons 18 and 19 of the Inppl1 gene are deleted, resulting in the decreased expression of a 57 amino acid-truncated SHIP2 protein, as compared with Ship2 +/+ mice expressing a 1257 amino acids wild type SHIP2 protein.
Removal of this 57 amino acid-region certainly results in a catalytically-inactive Ship2 protein, as predicted by the literature and measured by a phosphate release assay using PtdIns(3,4,5)P3 as a substrate (Dubois et al., 2012) . However, the effect of this specific truncation on the binding to SHIP2 interacting partners was not investigated, preventing any conclusion on the role of SHIP2 docking properties in OPS pathology. By contrast, in human OPS, the majority of mutations either creates a stop codon directly or results in a downstream stop codon. These mutations are predicted to result either in a null allele after nonsense-mediated mRNA decay or in a null catalytic activity (Below et al., 2013; Huber et al., 2013; Iida et al., 2013; Fradet and Fitzgerald, 2017) . Inppl1 missense mutations have also been detected in human OPS: they are located in the catalytic domain and presumably inactivate the 5-phosphatase function of the SHIP2 protein (Below et al., 2013; Huber et al., 2013; Iida et al., 2013; Fradet and Fitzgerald, 2017) . Again, the effect of these SHIP2 mutations detected in OPS patients on the binding to SHIP2 protein partners was not investigated. Nor was it investigated on the SHIP2 protein incubated with the AS1949490 SHIP2 inhibitor which reproduces in this study most if not all alterations detected after Ship2 genetic inactivation. Altogether, the high phenotypic variability within human OPS patients and with murine OPS may be due to the diversity of the mutations involved and their effects on the persistence (or not) of a truncated/mutated SHIP2 protein and on the binding to SHIP2 protein partners. It is noteworthy here that the complete absence of SHIP2 protein expression in Sleeman's Ship2 knock-out mice did not show a severe skeletal phenotype either (Sleeman et al., 2005) . An alternative hypothesis is that the severity of the disease is a consequence of a deleterious ratio between the many different phosphatases and kinases which finally control phosphoinositides levels in a specific cell type, like chondrocytes in our case. Thus, the inactivation of a single phosphatase or kinase in different species may result in a small difference in the ratio between the different phosphoinositide levels in a given cell type but in a significant difference in the severity of the phenotype. An extreme example of this concept is OCRL: inactivating mutations in this 5-phosphatase result in the Lowe syndrome in man but in no obvious phenotype in mouse (Jänne et al., 1998) .
One noteworthy result in our study is the confirmation that SHIP2 plays an important role during endochondral ossification: growth plate histology and mineralization are both affected in human and mouse OPS. These alterations can be the consequence of SHIP2 inactivation in many cell types, both outside and/or inside the bone. Our results revealed that intrinsic Ship2 Δ/Δ bone defects are sufficient to induce characteristic OPS alterations in bone growth, histology and mineralization ex vivo. Thus, SHIP2 inactivation in cells residing outside the growing bone does not seem to play a major role in the OPS phenotype, reinforcing the hypothesis that bone cells including osteoprogenitor cells, osteoblasts, osteoclasts and/or chondrocytes are essential in OPS. Since in Ship2 Δ/Δ mice no obvious alteration was detected in cortical bone thickness, a parameter that is highly dependent on membranous ossification and, on the contrary to endochondral ossification, does not implicate chondrocytes, we decided to concentrate our analyses on chondrocytes in this study. Unfortunately, attempts to investigate if SHIP2 inactivation specifically in chondrocytes is sufficient to recapitulate the skeletal OPS phenotype failed, due to an unexplained low level of Ship2 gene recombination in vivo and the consecutive persistence of a large amount of the wild type SHIP2 protein in chondrocytes of SHIP2 flox/flox Cre mice. Thus, we cannot exclude that alteration in other bone cells than chondrocytes also contribute to OPS pathology.
A second important and unexpected result in our study is the demonstration that osteocalcin plays an essential role in the mineralization defect observed in vitro in chondrocytes when SHIP2 is inactivated and, possibly, in murine OPS. Indeed, expression of osteocalcin is significantly increased in different models of SHIP2-inactivated chondrocyte cultures whereas production of mineralized nodules is systematically and markedly decreased. Targeting osteocalcin mRNA in cultured chondrocytes with specific shRNA increased the production of mineralized nodules. These results are in agreement with results obtained in osteocalcin knock-out mice which lack both osteocalcin genes expressed in the bone (Ducy et al., 1996) . Indeed, in these osteocalcin null mice, the absence of osteocalcin is associated with increased bone formation rate, bone mass and mineral to matrix ratio, as well as with larger hydroxyapatite crystal size, i.e. the opposite phenotype observed in cultured chondrocytes lacking SHIP2. Interestingly, the osteoblast overexpression of osteocalcin in α1(I)Col-Osteocalcin transgenic mice had no effect on bone mineralization (Murshed et al., 2004) , suggesting that chondrocyte-specific -and not osteoblast-specific -overexpression of osteocalcin is responsible for the decreased mineralization observed in the absence of SHIP2 in our in vivo and in vitro models. Since both osteopontin and osteocalcin are inhibitors of bone mineralization (Bailey et al., 2017) , the finding that osteopontin mRNA and protein levels are also increased in SHIP2-inactivated chondrocyte cultures reinforce the argument that loss of SHIP2 results in mineralization defect.
Finally, a third important result in our study is the role of the MEK-Erk1/2 signaling pathway in the OPS phenotype. Indeed, levels of p-MEK and p-Erk1/2 are significantly increased in SHIP2-inactivated chondrocytes in response to serum and IGF-1, but not to FGF2, as compared with control chondrocytes. Furthermore, treatment of SHIP2-inactivated chondrocytes and bones with a MEK inhibitor partially rescues the production of mineralized nodules, the size of the hypertrophic chondrocytes zone and bone growth, raising the possibility and the hope of a treatment that could partially reduce the phenotype of this rare but severe condition. Constitutive activation of MEK-Erk1/2 signaling pathway in chondrocytes is known to cause dwarfism in transgenic mice, with similar defects in growth plate differentiation as observed in Ship2 Δ/Δ mice (Murakami et al., 2004) . Indeed, transgenic mice that express a constitutively active mutant of MEK1 specifically in chondrocytes show increased phosphorylation of Erk1/2, shortened axial and appendicular skeleton, craniofacial dysmorphism with a round skull and shortened snout, delayed bone mineralization and reduction of the hypertrophic chondrocyte zone, all very similar to Ship2 Δ/Δ mice. Chondrocyte proliferation and the proliferative zone are not affected in these MEK1 transgenic mice (Murakami et al., 2004) . Despite the fact that activating mutations in FGF receptor 3 (FGFR3) also cause a similar short-limbed dwarfism with similar growth plate alterations in man and mouse (Su et al., 2008 (Su et al., , 2010 , we found no evidence for increased MEK-Erk1/2 phosphorylation in SHIP2-inactivated chondrocytes in response to FGF2. By contrast, IGF-1 stimulation of SHIP2-inactivated chondrocytes reproduced the MEK-Erk1/2 overactivation observed with serum stimulation. IGF-1 has been reported to control key signaling pathways and differentiation steps during endochondral ossification, particularly in hypertrophic chondrocytes (Cooper et al., 2013; Wang et al., 2014; Yang et al., 2017) . Many studies in the literature clearly indicate that SHIP2 inhibition may lead to MAPK overactivation in response to growth factors or that, alternatively, SHIP2 overexpression may lead to reduce MAPK activation (Blero et al., 2001; Sasaoka et al., 2003; Kagawa et al., 2005; Artemenko et al., 2009; Jurynec et al., 2010; Dubois et al., 2012; Agollah et al., 2014; Fafilek et al., 2018) . Several hypotheses have been proposed and include non-catalytic and catalytic mechanisms. First, SHIP2 might function through its SH2 domain to compete with and displace molecules such as Shc and Grb2 from the activated receptor tyrosine kinase, and thereby reduce the number of active signaling complexes (Sasaoka et al., 2003; Kagawa et al., 2005) . Similarly, functional studies on SHIP1, which is homologous to SHIP2, have shown that this 5-phosphatase negatively regulates MAPK through inhibition of the binding of a Grb2/SOS Ras guanine nucleotide exchange factor complex to the Shc adapter protein, which is an event that is necessary for Ras activation (Tridandapani et al., 1997; Sharma et al., 2005) . Second, about the catalytic regulation of MAPK by SHIP2, PdtIns(3,4,5)P3 could potentially lead to membrane recruitment of pleckstrin homology (PH) domain-containing proteins other than Akt that subsequently amplify growth factor-induced activation of Ras, as reported for antigen receptor signaling in lymphocytes (Readinger et al., 2009) and suggested for HGF and VEGF receptors in lymphatic endothelial cells (Agollah et al., 2014) .
Many studies have established that SHIP2 negatively influences Akt activity, essentially by recognizing PdtIns(3,4,5)P3 as a substrate (Ramos et al., 2018 (Ramos et al., , 2019 . However, the impact of SHIP2 on Akt activity is very much cell type-dependent: in the colorectal cancer HCT116 cell line, Akt phosphorylation was reduced when SHIP2 expression was decreased, without any change in cell proliferation (Hoekstra et al., 2016) . When cultured fibroblasts derived from OPS patients were stimulated during 5 min by EGF, p-PKB S473 was also decreased as compared to non-affected individuals (Ghosh et al., 2017) . In SHIP2-inactivated chondrocytes, p-Akt on S473 and T311 was not increased when stimulated with serum, IGF-1 or FGF2, as compared with control chondrocytes. This result is in agreement with the fact that Akt deletion in knock-out mice -but not Akt overexpression or overactivation -is associated with severe dwarfism and delayed bone ossification (Peng et al., 2003; Ulici et al., 2009 ).
In conclusion, our results indicate that Ship2 Δ/Δ mice represent a relevant model for human OPS. They also highlight the important role of SHIP2 in chondrocytes during endochondral ossification and its different differentiation steps. A role of osteocalcin in mineralized nodules production is firmly established. Finally, our data point out to a role of the MEK-Erk1/2 signaling pathway in the OPS phenotype as observed in our mice model.
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